Zafgen, Inc. (ZFGN) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a report published on Friday morning.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine upgraded shares of Zafgen from a strong sell rating to a sell rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $6.50.
Zafgen (ZFGN) opened at 3.58 on Friday. The firm’s market capitalization is $98.39 million. The firm has a 50-day moving average of $3.48 and a 200-day moving average of $4.02. Zafgen has a 52-week low of $2.89 and a 52-week high of $5.46.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter last year, the company earned ($0.55) earnings per share. On average, equities research analysts forecast that Zafgen will post ($2.23) EPS for the current fiscal year.
In other Zafgen news, insider Dennis D. Kim bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The shares were acquired at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the transaction, the insider now directly owns 21,443 shares in the company, valued at $72,691.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 21.20% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC boosted its position in Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 10,327 shares during the period. Algert Global LLC acquired a new stake in Zafgen during the 2nd quarter worth approximately $123,000. Nine Chapters Capital Management LLC acquired a new stake in Zafgen during the 1st quarter worth approximately $170,000. Wells Fargo & Company MN boosted its position in Zafgen by 1,290.3% during the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Zafgen during the 2nd quarter worth approximately $259,000. Institutional investors and hedge funds own 48.52% of the company’s stock.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.